Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Shenzhen Hepalink Pharmaceutical Group Co's
Operating Income
for the
three
months ended in Mar. 2026 was $29.4 Mil. Shenzhen Hepalink Pharmaceutical Group Co's Interest Expense for the
three
months ended in Mar. 2026 was $-1.9 Mil.
Shenzhen Hepalink Pharmaceutical Group Co's interest coverage for the quarter that ended in Mar. 2026 was 15.54.
The higher the ratio, the stronger the company's financial strength is.
Shenzhen Hepalink Pharmaceutical Group Co (OTCPK:SHEZF) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Shenzhen Hepalink Pharmaceutical Group Co Interest Coverage Related Terms
Shenzhen Hepalink Pharmaceutical Group Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Shenzhen Hepalink Pharmaceutical Group Co Interest Coverage Chart
Shenzhen Hepalink Pharmaceutical Group Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Hepalink Pharmaceutical Group Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen Hepalink Pharmaceutical Group Co Interest Coverage vs Drug Manufacturers Industry
Shenzhen Hepalink Pharmaceutical Group Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a Interest Coverage of 15.54 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors. This is 233% above median its historical median of 4.66. Over the past decade, Shenzhen Hepalink Pharmaceutical Group Co's Interest Coverage has ranged from 2.14 to 11.17. According to the industry distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #360 out of 684 companies in the Drug Manufacturers industry, placing it in the top 52.6%.
Is Shenzhen Hepalink Pharmaceutical Group Co's Interest Coverage too high?
Shenzhen Hepalink Pharmaceutical Group Co's current Interest Coverage of 15.54 is 233% above median its 10-year median of 4.66. Over the past 10 years, this metric has ranged from a low of 2.14 to a high of 11.17. The Drug Manufacturers industry median Interest Coverage is 12.77. Shenzhen Hepalink Pharmaceutical Group Co's value of 15.54 is 21.7% above this industry median. Based on the distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #360 out of 684 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shenzhen Hepalink Pharmaceutical Group Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Hepalink Pharmaceutical Group Co's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #360 out of 684 companies for Interest Coverage. This places Shenzhen Hepalink Pharmaceutical Group Co in the lower half of its industry. The industry median Interest Coverage is 12.77. Shenzhen Hepalink Pharmaceutical Group Co's value of 15.54 is 21.7% above this benchmark. Historically, Shenzhen Hepalink Pharmaceutical Group Co's own Interest Coverage has ranged from 2.14 to 11.17 over the past decade. While the company's 10-year median is 4.66 vs. the industry median of 12.77, Shenzhen Hepalink Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.77, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen Hepalink Pharmaceutical Group Co's current Interest Coverage of 15.54 is 21.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen Hepalink Pharmaceutical Group Co's current Interest Coverage is 15.54, which is 233% above median its own 10-year median of 4.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Hepalink Pharmaceutical Group Co stock overvalued right now?
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a current Interest Coverage of 15.54. The stock's GF Value™ is $0.61, compared to a current price of $0.47 — trading 23% below its estimated fair value. The current Interest Coverage is 15.54, which is 233% above median its 10-year median of 4.66 and 21.7% above the Drug Manufacturers industry median of 12.77. Shenzhen Hepalink Pharmaceutical Group Co's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Shenzhen Hepalink Pharmaceutical Group Co (SHEZF), the current Interest Coverage is 15.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of $0.47 is trading 23% below its estimated GF Value™ of $0.61.
Key valuation signals for SHEZF:
Interest Coverage: 15.54 (233% above median its 10-year median of 4.66)
GF Value™: $0.61 vs. price of $0.47 (23% below fair value)
Industry Position: 21.7% above the Drug Manufacturers median (#360 of 684)
No single metric tells the full story. See the SHEZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen Hepalink Pharmaceutical Group Co Business Description
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company. Along with its subsidiary, it is engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development in Asia, Europe, North America, and Australia, and investment business in Asia and North America. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products; Active pharmaceutical ingredients; CDMO business; and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from Europe and the USA.
69GF Score
Get the complete analysis for SHEZF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHEZF has been successfully added to your 
